Kidney Cancer Coverage from Every Angle

Rana R. McKay, MD, on Renal Cell Carcinomas: The Potential Role for Atezolizumab and Bevacizumab

Posted: Tuesday, February 19, 2019

Rana R. McKay, MD, of the University of California, San Diego, talks about how these agents may fit in the future treatment landscape, in light of phase II study findings on atezolizumab and bevacizumab in non–clear cell as well as clear cell renal cell carcinomas with sarcomatoid differentiation.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.